For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | - | - | - | 0 |
| Cost of sales | - | - | - | 0 |
| Gross profit | - | - | - | 0 |
| Board of directors compensation | 105,750 | 105,750 | 105,750 | 105,750 |
| General and administrative | 11,983 | 12,048 | 10,165 | 17,031 |
| Total expenses | 117,733 | 117,798 | 115,915 | 122,781 |
| Loss from operations before other income and (expense) | -117,733 | -122,487.75* | - | - |
| Loss from operations before loss on liability settlement | - | - | -115,915 | -122,781 |
| Legal settlement | 15,322 | - | - | - |
| Loss on liability settlement | - | -3,882.75* | - | 0 |
| Total other income and (expense) | 15,322 | - | - | - |
| Net loss for the period | -102,411 | -118,605 | -115,915 | -122,781 |
| Basic EPS | 0 | -0.004 | 0 | 0 |
| Diluted EPS | 0 | -0.004 | 0 | 0 |
| Basic Average Shares | 33,521,755 | 33,853,603 | 33,521,755 | - |
| Diluted Average Shares | 33,521,755 | 33,539,219 | 33,521,755 | 33,521,755 |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)